KRONOX - Kronox Lab
📢 Recent Corporate Announcements
Kronox Lab Sciences reported a steady but modest performance for the quarter ended December 31, 2025, with revenue from operations growing 5.2% YoY to ₹25.27 crore. Net profit for the quarter stood at ₹6.59 crore, showing a marginal increase from ₹6.53 crore in the same period last year. On a sequential basis, both revenue and profit saw a slight dip compared to the September 2025 quarter. For the nine-month period, the company maintained stability with a PAT of ₹19.66 crore compared to ₹19.15 crore in the previous year.
- Revenue from operations increased to ₹2,527.40 lakhs in Q3 FY26 from ₹2,401.11 lakhs in Q3 FY25.
- Net Profit (PAT) for the quarter recorded at ₹658.90 lakhs, up marginally from ₹652.86 lakhs YoY.
- Total expenses for the quarter rose to ₹1,780.85 lakhs compared to ₹1,600.35 lakhs in the previous year's quarter.
- Nine-month (9M FY26) PAT reached ₹1,965.79 lakhs, representing a 2.6% growth over 9M FY25.
- Basic and Diluted Earnings Per Share (EPS) for the quarter stood at ₹1.78, compared to ₹1.77 in the year-ago period.
Kronox Lab Sciences Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ending December 31, 2025. The certificate, issued by Kfin Technologies Limited, confirms that the details of securities dematerialized or rematerialized have been correctly furnished to the stock exchanges. This is a standard procedural filing required by all listed companies in India to ensure shareholding records are accurately maintained. There are no material financial or operational updates contained in this specific announcement.
- Submission of Regulation 74(5) certificate for the quarter ending December 31, 2025.
- Certificate issued by Kfin Technologies Limited, the company's Registrar and Share Transfer Agent.
- Confirms that all securities dematerialized or rematerialized were reported to NSE and BSE.
- Standard compliance procedure involving both NSDL and CDSL depositories.
Kronox Lab Sciences Limited has informed the stock exchanges that its trading window for dealing in company securities will be closed starting January 1, 2026. This closure is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations for the upcoming announcement of financial results. The closure pertains to the unaudited financial results for the quarter and nine-month period ending December 31, 2025. The window will reopen 48 hours after the board meeting results are officially disclosed.
- Trading window closure for designated persons effective from January 1, 2026.
- Closure is in preparation for the unaudited financial results for the quarter ending December 2025.
- Trading window will remain closed until 48 hours after the board meeting announcement.
- The specific date for the board meeting to approve results will be communicated separately.
- Filing is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Kronox Lab Sciences Limited has informed the stock exchanges that its trading window for dealing in company securities will be closed for designated persons. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, for the upcoming announcement of financial results. The closure pertains to the unaudited financial results for the quarter and nine months ending December 31, 2025. The window will reopen 48 hours after the results are officially declared to the exchanges.
- Trading window closure for all designated persons and insiders starting from the end of the quarter.
- Closure is related to the unaudited financial results for the quarter and nine months ending December 31, 2025.
- The trading window will remain closed until 48 hours after the board meeting results are made public.
- The specific date for the Board Meeting to approve the results will be announced separately.
Financial Performance
Revenue Growth by Segment
The company operates in a single reportable segment: Manufacturing of High Purity Speciality Fine Chemicals. Revenue from operations for Q2 FY26 was INR 25.53 Cr, representing a 2.71% growth compared to INR 24.86 Cr in Q2 FY25. However, H1 FY26 revenue of INR 49.82 Cr showed a marginal decline of 0.46% compared to INR 50.05 Cr in H1 FY25, indicating flat performance in the first half of the year.
Geographic Revenue Split
Not disclosed in available documents. The company operates from its registered and corporate offices in Vadodara, Gujarat, with manufacturing units in Padra and a new unit planned in Dahej.
Profitability Margins
Net Profit Margin for H1 FY26 stood at 26.23%, improving from 25.22% in H1 FY25. This margin expansion was driven by a 3.51% increase in Profit After Tax (INR 13.07 Cr vs INR 12.62 Cr) despite stagnant revenue, suggesting better cost control or a shift toward higher-margin products.
EBITDA Margin
EBITDA margin for H1 FY26 is approximately 37.41% (calculated as PBT of INR 17.73 Cr + Depreciation of INR 0.87 Cr + Finance Costs of INR 0.04 Cr over Revenue of INR 49.82 Cr). This represents a healthy core profitability profile for the specialty chemicals sector.
Capital Expenditure
The company invested INR 3.03 Cr in Property, Plant, and Equipment (including CWIP) during H1 FY26. A significant upcoming CAPEX is planned for the construction of UNIT-IV at Dahej, following the receipt of 'Consent to Establish' from the GPCB in November 2025.
Credit Rating & Borrowing
The company maintains a very low debt profile. Total borrowings as of September 30, 2025, stood at INR 2.61 Cr (INR 1.31 Cr non-current and INR 1.30 Cr current) against a total equity base of INR 101.40 Cr, resulting in a negligible debt-to-equity ratio.
Operational Drivers
Raw Materials
The company consumes chemical raw materials for manufacturing High Purity Speciality Fine Chemicals. Cost of materials consumed in H1 FY26 was INR 23.08 Cr, representing 46.33% of total revenue.
Capacity Expansion
The company currently operates units in Padra, Vadodara. It has received GPCB 'Consent to Establish' for UNIT-IV at Dahej as of November 10, 2025. Construction is set to commence shortly, which will significantly expand the total manufacturing capacity for specialty chemicals.
Raw Material Costs
Raw material costs as a percentage of revenue decreased slightly to 46.33% in H1 FY26 from 46.28% in H1 FY25. Total material consumption was INR 23.08 Cr, down 0.36% YoY, tracking closely with the slight revenue decline.
Manufacturing Efficiency
Depreciation and amortization expenses rose 28.34% YoY to INR 0.87 Cr in H1 FY26, reflecting recent additions to the fixed asset base and modernization of existing facilities.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be driven by the operationalization of UNIT-IV at Dahej, which has recently cleared regulatory hurdles. The company is focusing on the high-margin 'High Purity' segment of the specialty chemicals market, targeting applications in pharmaceuticals, nutraceuticals, and biotech. The strategy includes leveraging its debt-free balance sheet to fund expansion through internal accruals.
Products & Services
High Purity Speciality Fine Chemicals used as reagents and raw materials in laboratory testing, pharmaceutical manufacturing, and biotech research.
Brand Portfolio
KRONOX
New Products/Services
The company is expanding its product portfolio within the high-purity chemical range to cater to the evolving standards of the pharmaceutical industry.
Market Expansion
Expansion is focused on the Dahej industrial zone (UNIT-IV) to tap into the chemical hub's logistics and export advantages.
External Factors
Industry Trends
The specialty chemicals industry is shifting toward higher purity standards and 'China Plus One' sourcing strategies. KRONOX is positioning itself to capture this shift by expanding its Gujarat-based manufacturing footprint.
Competitive Landscape
Competes with both domestic specialty chemical manufacturers and international reagent suppliers in the high-purity niche.
Competitive Moat
The company's moat lies in its ability to manufacture chemicals to extremely high purity levels, which requires stringent quality control and specialized processes. This creates high switching costs for pharmaceutical clients who have validated KRONOX as a supplier.
Macro Economic Sensitivity
Highly sensitive to the growth of the Indian pharmaceutical and healthcare sectors, which are primary consumers of high-purity chemicals.
Consumer Behavior
Increased focus on drug safety and precision in lab testing is driving demand for higher-grade specialty chemicals.
Geopolitical Risks
Trade barriers or changes in export-import policies for chemical precursors could affect procurement costs and international sales.
Regulatory & Governance
Industry Regulations
Operations are governed by GPCB (Gujarat Pollution Control Board) norms and Indian Accounting Standards (Ind AS 34). The company must adhere to specific manufacturing standards for chemicals used in pharmaceutical applications.
Environmental Compliance
The company recently secured Environmental Clearance and GPCB 'Consent to Establish' for its Dahej unit, indicating compliance with stringent Gujarat pollution control norms.
Taxation Policy Impact
Effective tax rate for H1 FY26 was approximately 26.32% (Tax expense of INR 4.67 Cr on PBT of INR 17.73 Cr).
Legal Contingencies
No major pending court cases or litigation values were disclosed in the financial results or announcements.
Risk Analysis
Key Uncertainties
The primary uncertainty is the timeline for the completion and commissioning of UNIT-IV at Dahej, which is critical for future growth. Regulatory changes in environmental norms for chemical units in Gujarat also pose a potential risk.
Geographic Concentration Risk
High geographic concentration with all existing and planned units located in Gujarat (Padra and Dahej).
Third Party Dependencies
Dependency on specialized raw material suppliers for chemical precursors; however, specific vendor names were not disclosed.
Technology Obsolescence Risk
Risk is low as the demand for high-purity basic chemicals is stable, but the company must continuously upgrade its purification technologies.
Credit & Counterparty Risk
Trade receivables stood at INR 20.53 Cr as of September 30, 2025, representing approximately 41% of H1 revenue, indicating a significant but manageable credit exposure to clients.